Loading company
GH Research PLC
GHRS · Nasdaq · ·
Next earnings: November 5, 2026
$24.70+5.3%Sep 29 close
- 1M
- -11.6%
- 6M
- +89.6%
- 1Y
- +72.7%
- 5Y
- +16.1%
GHRS · Nasdaq · ·
Next earnings: November 5, 2026
$24.70+5.3%Sep 29 close
GH Research PLC is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2025, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2025 | 3 months toDec 31, 2024 | Change |
|---|---|---|---|
| Profit | -$14.1M | -$8.8M | -60.61% |
| Profit per share | -$0.23 | -$0.17 | -35.29% |
| Free Cash Flow | -$10.7M | -$8.6M | -25.13% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
GH Research PLC has no earnings call transcript available.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. GH Research PLC’s initial focus is on developing its novel and proprietary mebufotenin therapies for the treatment of patients with TRD.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K GH Research PLC filed on August 6, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.